Upcoming Technologies to Facilitate More Efficient Biologics Manufacturing - Choosing the right tools to enhance the process. - BioPharm International


Upcoming Technologies to Facilitate More Efficient Biologics Manufacturing
Choosing the right tools to enhance the process.

BioPharm International
Volume 22, Issue 2

Three Viresolve Pro Micro devices were tested for each MAb. The MAb 1 solution was approximately 6.0 g/L protein concentration. The MAb 2 solution was approximately 4.5 g/L protein concentration. After adding a 1% v/v MMV virus spike, feeds were filtered through a 0.22 m filter. As can be seen from the results obtained with MAb 2, even at 90% flow decay, no passage of MMV was observed. With MAb 1, no passage of MMV was observed even after 13 kg/m2 of the protein was challenged. It was not possible to run to such high flow decays with MAb 1, because adequate feed material was not available. The results presented in Table 2 demonstrate robust virus clearance performance across a range of volumetric loadings, mass loadings, and flow decay points.

Figure 7 shows capacity performance of Viresolve Pro Micro devices on 16 proteins tested. Most feed streams were tested at 30 psig (2.1 bars) using constant pressure operation. No prefiltration was used except the industry standard practice of a sterilizing grade filter. The achieved protein mass capacity averaged 6,900 g/m2 when limited to 4 h processing time and 75% flow decay. The results demonstrate achievement of high mass capacities and short processing times with Viresolve Pro devices.

Further, the BGT has been developed as a new, proprietary release test that uses a two- component gas mixture, in which there is a large difference in permeability between the two gases across a wetted membrane and concentration is measured on the downstream side. A deviation from the expected concentration is an indication of the presence of a defect that could negatively affect the virus-retention capabilities of the device. Data presented in Table 3 demonstrates the superior sensitivity of this test in comparison to the traditional air-water flux test. Three devices, constructed from the same membrane lot, were tested with air-water diffusion, BGT, and virus retention testing. Although the BGT could discriminate among devices with small differences in retention, the air-water diffusion test could not.

In summary, the Viresolve Pro Solution can provide high capacities and high viral retention under a range of processing conditions. This performance allows for increased productivity in manufacturing operations, often reduces the system size required for manufacturing. The flexibility of the fully disposable devices allows for ease of use and speed in process development and manufacturing. Enhanced release testing delivers a higher degree of virus-retention assurance.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here